logo

Abeona Therapeutics Inc. (ABEO)



Trade ABEO now with
  Date
  Headline
7/9/2020 7:42:52 AM Abeona Therapeutics Appoints Michael Amoroso As Chief Commercial Officer
7/8/2020 7:34:40 AM Abeona Reinitiates Enrollment In EB-101 Pivotal Phase 3 VIITAL Study In RDEB
6/17/2020 7:36:31 AM Abeona Therapeutics Names George Migausky And Paul Mann Independent Directors
3/17/2020 7:47:24 AM Abeona: First Patient Treated In Pivotal Phase III Clinical Trial On EB-101
6/26/2019 8:31:21 AM Abeona Therapeutics Appoints Victor Paulus As SVP Of Regulatory Affairs
6/18/2019 8:41:21 AM Abeona Receives FDA Fast Track Designation For ABO-202 AAV9 Gene Therapy
4/4/2019 8:37:44 AM Abeona Therapeutics Receives FDA Fast Track Designation For ABO-101 For Sanfilippo Syndrome Type B (MPS IIIB)
1/8/2019 1:30:14 PM Abeona Therapeutics Appoints Christine Silverstein As CFO
11/9/2018 4:48:00 PM Abeona Therapeutics Q3 Loss Per Share $0.34 Vs. $0.13 Last Year
11/5/2018 7:15:12 AM Abeona Therapeutics And REGENXBIO Announce Worldwide Licenses For Rare Lysosomal Storage Disorders
9/12/2018 8:47:25 AM Abeona Therapeutics Announces Authorization To Begins Phase 1/2 Gene Therapy Study For Patients With MPS IIIB In Spain
5/31/2018 8:51:09 AM Abeona Therapeutics Announces Opening Of The Elisa Linton Center For Rare Disease Therapies In Cleveland, Ohio
5/18/2018 9:32:39 AM Abeona Therapeutics Provides Update On MPS IIIA Gene Therapy Trial
5/18/2018 9:29:58 AM Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
5/17/2018 9:22:12 AM Abeona Announces Updated Clinical Data From Phase 1/2 Trial For EB-101